More exciting news from the Annual American Society of Clinical Oncology Meeting last week!
Onconova Therapeutics announced results from a Phase 2 study of oral rigosertib as a treatment for higher-risk myelodysplastic syndromes.
Myelodysplastic syndromes (MDS) are a group of cancerous conditions that prevent bone marrow from functioning normally. Currently, there is no cure for the conditions, but if you want to learn more about MDS, click here.
The rigosertib Phase 2 clinical trial focused on the biomarker (measurable substance whose presence is indicative of a disease) of bone marrow blast, and it was found that treatment with rigosertib resulted in an overall reduction of this bone marrow blast.
These results confirm earlier findings and suggest that rigosertib could be used to increase overall survival in MDS patients.
Following these exciting results, and with guidance from the U.S. FDA, rigosertib began being tested in a randomized, international Phase 3 trial known as INSPIRE, using patients with advanced and resistant forms of MDS.
An interim analysis is expected in the coming months, and the overall hope for the trial is survival in all participants.
If the results from this Phase 3 trial further prove the safety and efficacy of rigosertib, MDS patients may eventually have a convenient, strong working, and more effective treatment option for their rare condition.
If you are interested in learning more about oral rigosertib, click here!
